NCT06740552View on ClinicalTrials.gov

Evolocumab in Patients with Multivessel Coronary Disease After Acute Myocardial Infarction: a Target Trial Emulation

Active, not recruitingOBSERVATIONAL
Enrollment

912

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Multivessel Coronary Artery DiseaseAcute Myocardial Infarction (AMI)
Interventions
DRUG

Evolocumab

Evolocumab 140mg every two weeks

DRUG

Lipid Lowering Medication

Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.

Trial Locations (1)

200000

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
collaborator

Shanghai Shenkang Hospital Development Center

UNKNOWN

collaborator

Tongji Hospital

OTHER

collaborator

RenJi Hospital

OTHER

collaborator

Shanghai 10th People's Hospital

OTHER

collaborator

Shanghai General Hospital, China

OTHER

lead

Shanghai Zhongshan Hospital

OTHER